Evidence map›Paper›PMID 42489814›Full record

ArticleJournal of neuro-oncology2026

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.

Patrick P Carriere, Ory Haisraely, Ashley Aaroe, Kayode Ahmed, Ryan Lewis, Darien Colson-Fearon, McArthur Bolden, Todd A Swanson, Thomas H Beckham, Chenyang Wang and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Patrick P Carriere *Division of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Ory Haisraely *Division of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Ashley AaroeDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kayode AhmedDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Ryan LewisDepartment of Information Technology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Darien Colson-FearonDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
McArthur BoldenDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Todd A SwansonDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Thomas H BeckhamDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Chenyang WangDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Brian DeDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Subha PerniDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Martin C TomDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Jing LiDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Susan McGovernDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Mary F McAleerDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Amol GhiaDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Wen JiangDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Caroline ChungDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
David GrosshansDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Leomar BallesterDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yoshua EsquenaziDepartment of Neurosurgery, UTHealth Houston, Houston, TX, USA.
Carlos Kamiya-MatsuokaDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Debra Nana YeboaDivision of Radiation Oncology, Department of CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. dnyeboa@mdanderson.org.ORCID https://orcid.org/0000-0002-2901-7477

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIDH-wt diffuse gliomas with histologic grade 2-3 features and distinct molecular characteristics are now classified as molecular glioblastoma, yet outcomes and optimal management remain incompletely defined in a contemporary cohort.

methodsAdults with histologic grade 2-3 IDH-wt gliomas diagnosed from 1996 to 2019 were retrospectively identified. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier methods, with Cox regression used to assess prognostic factors. To account for noncanonical IDH mutations, subgroup analyses were performed in those age > 55 or with next generation sequence (NGS) IDH testing.

resultsA total of 134 patients were included, with a median follow-up of 29.8 months. Median OS was 35 months (95% CI: 28.8-43), and median PFS was 20.9 months (95% CI: 14.5-27.4). Grade 2 tumors demonstrated significantly improved outcomes compared to grade 3 tumors (median OS 94.5 vs. 29.8 months; median PFS 50.6 vs. 15.3 months). Among grade 3 tumors, sequential radiation and chemotherapy yielded a median OS of 29.8 months versus 29.8 months with concurrent chemoradiation followed by chemotherapy (p = 0.17); median PFS was 22.2 months versus.

conclusionIDH-wt gliomas with grade 2-3 histology have heterogeneous outcomes. Grade 3 tumors show survival comparable to molecular glioblastoma, while a subset of grade 2 tumors exhibit prolonged survival. Concurrent chemoradiation did not confer a survival advantage over sequential therapy in grade 3 tumors, supporting reevaluation of treatment intensity in selected patients.

Indexed as

Brain NeoplasmsGliomaIsocitrate DehydrogenaseAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedMutationNeoplasm GradingPrognosisRetrospective StudiesSurvival RateYoung AdultIDH1 protein, humanIsocitrate DehydrogenaseChemotherapyConcurrent chemoradiationIDH wildtype glioma radiotherapy managementMolecular glioblastomaMolecular grade 4 glioblastomaMolecular grade 4 glioma managementRadiotherapySequentialSequential radiation and chemotherapy

Identifiers

PMID42489814
PMCPMC13395831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.